Zhi Tong Cai Jing·2026-02-24 08:51Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1: Product Development - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), designed to lower serum triglycerides (TG) and LDL-C levels [1] - The total R&D investment for the SHR-1918 injection project has reached approximately 24.22 million yuan (unaudited) [1] Group 2: Market Context - The only other drug targeting the same pathway is Regeneron's EVKEEZA® (evinacumab-dgnb), which is projected to have global sales of about $216 million by 2025 according to EvaluatePharma [1]